CONTENTS:
• Housing: a fundamental component of drug policy [Editorial]. Zerger S., p. 91-93.
• The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Islam M.M., Topp L., Day C.A., Dawson A., Conigrave K.M., p. 94-102.
• Clients are central to any independent and rigorous evaluation of the services they use. Rowe J., p. 103-104.
• One stop shopping - bringing services to drug users. Bruce R.D., p. 104.
• Primary health care for people who inject drugs in low and middle income countries. Myers B.J., p. 105-106.
• Primary care is the best place to care for drug users. Ford C., p. 106.
• Windows of opportunity: adapting services to the needs of people who inject drugs. Nasiri B., p. 107.
• Maybe not perfect - but surely good enough? van Beek I., p. 108.
• Primary healthcare outlets that target injecting drug users: opportunity to make services accessible and acceptable to the target group. Mofizul Islam M., Topp L., Day C.A., Dawson A., Conigrave K.M., p. 109-110.
• Where harm reduction meets housing first: exploring alcohol's role in a project-based housing first setting. Collins S.E., Clifasefi S.L., Dana E.A., Andrasik M.P., Stahl N., Kirouac M., et al., p. 111-119.
• Heroin users' views and experiences of physical activity, sport and exercise. Neale J., Nettleton S., Pickering L., p. 120-127.
• Street-level policing in the Downtown Eastside of Vancouver, Canada, during the 2010 Winter Olympics. Small W., Krusi A., Wood E., Montaner J., Kerr T., p. 128-133.
• Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands. Brunt T.M., Niesink R.J., van den Brink W., p. 134-140.
• Rejuvenating harm reduction projects for injection drug users: Ukraine's nationwide introduction of peer-driven interventions. Smyrnov P., Broadhead R.S., Datsenko O., Matiyash O., p. 141-147.
• Are drug detection dogs and mass-media campaigns likely to be effective policy responses to psychostimulant use and related harm? Results from an agent-based simulation model. Dray A., Perez P., Moore D., Dietze P., Bammer G., Jenkinson R., et al., p. 148-153.
• Ayahuasca and the process of regulation in Brazil and internationally: implications and challenges. Labate B.C., Feeney K., p. 154-161.
• Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Lucas G.M., Beauchamp G., Aramrattana A., Shao Y., Liu W., Fu L., et al., p. 162-165.
• Awareness of legal blood alcohol concentration limits amongst respondents of a national roadside survey for alcohol and traffic behaviours in Brazil. da Conceicao T.V., De Boni R., Duarte Pdo C., Pechansky F., p. 166-168.
• Scale-up of opioid substitution therapy in India: opportunities and challenges. Kumar M.S., Agrawal A., p. 169-170.
• Opioid substitution treatment in a public health setting: a collaboration between hospitals and NGOs in the Punjab. Singh R.R., Ambekar A., p. 170-171.